What happened with ARCT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Arcturus Therapeutics Holdings Inc. develops vaccines against infectious diseases and treatments for rare liver and respiratory diseases. Its STARR technology uses self-amplifying mRNA, while its LUNAR delivery system carries the genetic material into cells. CSL Seqirus licenses these technologies for vaccines and supplies most of Arcturus’s revenue through license and milestone payments and development and manufacturing services. A smaller revenue stream comes from research funding, mainly from the U.S. government agency BARDA for a pandemic influenza vaccine.
The CSL agreement gives Arcturus a share of net profits from COVID-19 vaccines and royalties on other covered vaccines, subject to contractual conditions. Its COVID-19 vaccine KOSTAIVE is sold in Japan through Meiji Seika Pharma, CSL Seqirus’s exclusive Japanese partner, but demand there has been weak. KOSTAIVE is also approved in the European Union and United Kingdom, though it has not been commercialized in Europe. It lacks U.S. approval, and the FDA requires additional clinical efficacy data.
Arcturus depends heavily on CSL Seqirus, which holds exclusive global rights in the licensed vaccine fields and leads much of their development and commercialization. Payments depend on development progress and vaccine sales, rather than a steady stream of direct medicine sales. Arcturus also develops its own treatments for ornithine transcarbamylase deficiency and cystic fibrosis; these remain experimental, not approved products.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Arcturus Therapeutics Holdings Inc.’s results depend heavily on CSL Seqirus’s vaccine development and commercialization decisions, milestone payments and KOSTAIVE sales, including distribution by Meiji Seika Pharma in Japan.
Moderna competes with Arcturus in COVID-19 vaccine sales and is developing an alternative treatment for OTC deficiency. Watch sales of its Spikevax and mNEXSPIKE vaccines for competitive pressure on KOSTAIVE; its OTC candidate is still preclinical, while Arcturus’s ARCT-810 is in Phase 2.
BioNTech sells Comirnaty with Pfizer in competition with Arcturus’s KOSTAIVE, and its influenza and COVID-19/influenza combination vaccines overlap with Arcturus’s CSL Seqirus-partnered pipeline. Progress in those vaccine programs shows how competition could extend beyond COVID-19.
Novavax sells a protein-based COVID-19 vaccine that competes with Arcturus’s KOSTAIVE, and both pursue influenza vaccines. Watch acceptance of Novavax’s vaccine: Arcturus says better-accepted competing products could prevent KOSTAIVE’s commercial success.
Pfizer commercializes Comirnaty with BioNTech against Arcturus’s KOSTAIVE, putting its vaccine sales directly in Arcturus’s competitive path. Its development of influenza and COVID-19/influenza combination vaccines also challenges the vaccine pipeline Arcturus has partnered with CSL Seqirus.
Ultragenyx Pharmaceutical is developing a gene therapy for the same OTC-deficiency patients Arcturus aims to treat with its Phase 2 mRNA candidate ARCT-810. Its OTC clinical progress is the relevant comparison for Arcturus’s liver-disease program, rather than sales of its already approved rare-disease medicines.
Sionna Therapeutics is developing combinations of drugs that modify CFTR protein function, offering a competing approach to Arcturus’s Phase 2 mRNA treatment ARCT-032 for cystic fibrosis. Watch its proprietary dual-combination trials; Sionna is still in clinical development, not selling an approved product.
Krystal Biotech’s cystic-fibrosis gene-therapy program could compete with Arcturus’s Phase 2 respiratory mRNA treatment ARCT-032. Watch that program’s progress rather than VYJUVEK sales, which come from its approved topical gene therapy for dystrophic epidermolysis bullosa, a different disease.
4D Molecular Therapeutics is developing a cystic-fibrosis treatment that could compete with Arcturus’s Phase 2 mRNA therapy ARCT-032. Its cystic-fibrosis development news is the relevant signal, not payments from Otsuka for rights to its separate retinal-disease treatment 4D-150.
Sanofi’s established influenza-vaccine business competes with the vaccines Arcturus is developing with CSL Seqirus. Sanofi sells vaccines worldwide, including to publicly funded organizations; watch its influenza offering, which switched to trivalent formulations in most geographies in 2025.
GSK’s clinical mRNA vaccines could compete with Arcturus’s CSL Seqirus-partnered COVID-19 and influenza programs. Watch its Phase 2 COVID-19 and influenza vaccines and Phase 1 combination vaccine: these mRNA programs have not yet secured health-authority approval.
CAMP4 Therapeutics’ CMP-001 could compete with Arcturus’s ARCT-810 for OTC-deficiency patients if CAMP4 advances its urea-cycle-disorder program through a partner and the candidates succeed clinically. Watch for that partnership and clinical progress; through December 31, 2025, CAMP4 had no product-sales revenue and had partly funded operations through licensing and collaborations.
GSK plc earningsGSK
GSK's report will show how its mRNA COVID-19, influenza, and combination-vaccine programs are progressing, and whether they could become future competition for the vaccines Arcturus is developing with CSL Seqirus.
Look for trial progress or clinical data on GSK's Phase 2 COVID-19 and influenza vaccines and its Phase 1 combination vaccine. Advancement or positive data would mean Arcturus and CSL Seqirus could face more clinical-stage competition; limited progress would leave less evidence of a rival moving closer, but would not show that Arcturus's candidates work or will be approved.
Sanofi earningsSNY
Sanofi's report will show how demand for its influenza vaccines is holding up after its switch to trivalent formulations in most markets, a signal of the established competition facing Arcturus and CSL Seqirus.
Look for Sanofi's reported influenza-vaccine sales and demand, particularly after its switch to trivalent formulations. Sustained demand would show that an established supplier still attracts buyers and vaccine recipients, making the future market harder for Arcturus and CSL Seqirus to win. Weak demand would mean less pressure from Sanofi's offering, but would not prove that the overall influenza-vaccine market is growing.
Ultragenyx Pharmaceutical Inc. earningsRARE
Ultragenyx Pharmaceutical's report will show how its gene-therapy program for OTC deficiency is progressing, a competing approach aimed at the same patients as Arcturus's ARCT-810.
Focus on trial progress or clinical data for Ultragenyx's OTC-deficiency program, not sales of its approved medicines for other rare diseases. Advancement or meaningful clinical data would show another treatment option developing for the same patients and raise the competitive bar for ARCT-810. Limited progress would offer less evidence of that alternative advancing, but would not prove ARCT-810 works or will be approved.
Sionna Therapeutics, Inc. earningsSION
Sionna Therapeutics' report will show how its CFTR-modifying drug combinations are progressing, a competing approach for the cystic-fibrosis patients Arcturus is targeting with ARCT-032.
Look for progress in Sionna's dual-combination trials and any clinical data. Trial advancement or meaningful data would show another treatment approach moving forward for the same cystic-fibrosis patients, adding to the competition ARCT-032 could face. Limited progress would leave that alternative less established, but would not show that ARCT-032 works or will be approved.
Moderna, Inc. earningsMRNA
Moderna's report will show sales and demand for Spikevax and mNEXSPIKE, helping distinguish strong mRNA-vaccine competition for Arcturus's KOSTAIVE from a weakening COVID-19 vaccine market.
Read Moderna's reported COVID-19 vaccine sales alongside its commentary on demand. Supported sales would show that the market still has buyers, but also that an established mRNA competitor is reaching them, making it harder for KOSTAIVE to gain ground. Weaker sales could mean less pressure from this rival, but could also signal a shrinking market that would be difficult for KOSTAIVE too.
Arcturus Therapeutics Holdings Inc. earningsThis company
Arcturus Therapeutics' report will show whether CSL collaboration revenue and government research reimbursements can keep supporting its research spending.
Compare CSL collaboration revenue and government reimbursements, such as BARDA funding, with research spending and cash used in operations. Stable CSL revenue, reimbursements that fund the eligible work, and contained spending and cash use would show that partners are still helping finance research. If CSL revenue weakens, reimbursements do not fill the gap, and spending and cash use remain high, Arcturus will depend more on its cash reserves or outside financing to keep programs going.
